UK MHRA approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only

The approval of a higher dose of semaglutide for obesity by the UK MHRA is significant as it could enhance treatment options for obesity management, thereby potentially increasing demand for Novo Nordisk's product.

Newsquawk StaffPublished On the live feed at 4 more headlines followed before this page went public
Newsquawk headlinesUTC

Russia's Kremlin says they are expecting US envoys Kushner and Witkoff to visit Moscow, although no official date has been set yet

[MARKET ANALYSIS] JPY gains on reports of a BoJ hike as soon as April and further jawboning

UK MHRA approves up to 7.2mg dose of semaglutide (Wegovy) for patients with obesity only

Russia announces plans to increase defence capabilities in the Arctic region as tensions around Greenland heighten

[MARKET ANALYSIS] Weaker sentiment across most indices; Basic Resources the biggest underperformer due to lower metal prices

Open the platform and use it. The whole workspace is free to try, with no signup and no card. When you want the headlines arriving live instead of on a delay, Newsquawk Pro is £24.99 for 7 days.

Free. No signup, no card.
Context

This news may bolster investor sentiment towards Novo Nordisk in the short term, but the broader implications on the healthcare sector and market dynamics will depend on subsequent demand and competitive responses.

Related headlines

The whole workspace, free to try.

Try it free